Clinical trials: HPV Vaccines
Anal Dysplasia, Human Papillomavirus
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell carcinoma…
- Conditions
- Anal Dysplasia, Human Papillomavirus, Anal Cancer
- Trial name
- HPV-SAVE (NCT02503111)
- Testing
- The Hyfrecator ® 2000 Electrosurgical System, Observation Alone
- Where
- 4 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen…
- Conditions
- Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
- Trial name
- NCT06866574
- Testing
- Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli), Aluminum Adjuvant
- Where
- 4 sites in China
- Volunteers
- 9,300 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Healthy, Human Papilloma Virus Infection
The Parents in Appalachia Receive Education Needed for Teen Project
This clinical trial studies an educational intervention for parents and providers in increasing human papillomavirus (HPV) vaccination rates in younger girls in Ohio Appalachia.
- Trial name
- PARENT (NCT01901770)
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
HPV-Related Cervical Carcinoma
Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake
This study aims to assess the effectiveness of targeted educational interventions in increasing the acceptability and knowledge of the HPV vaccine among females ages 12 through 26.
- Trial name
- NCT03337269
- Testing
- Educational video, Educational handout, Control
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Immunization Program, School Health Services
A School Health Center Intervention to Increase Adolescent Vaccination
The study will evaluate a health services intervention to increase uptake of adolescent vaccines (HPV, Tdap, meningococcal conjugate, and influenza) among students enrolled in five school health centers by improving the consent…
- Conditions
- Immunization Program, School Health Services, HPV Vaccines
- Trial name
- NCT01595542
- Testing
- Modified Vaccine Consent Form
- Where
- United States
- Volunteers
- 3,417 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HPV Infections
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
- Trial name
- HPV CSP01 (NCT00956553)
- Testing
- Cervarix, Gardasil
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Public Health England
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Hepatitis E Virus Infection
- Trial name
- NCT05415345
- Testing
- Cecolin, Hecolin
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Human Papillomavirus Infection
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and…
- Trial name
- NCT00988884
- Testing
- V503, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,241 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV, Human Papilloma Virus
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer.
- Conditions
- HPV, Human Papilloma Virus, Human Immunodeficiency Virus
- Trial name
- NOVA-HIV (NCT05495906)
- Testing
- Nonavalent HPV vaccine
- Where
- 10 sites in Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Infections, Papillomavirus
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This study will further evaluate induction of immune memory and anamnestic responses in women who previously took…
- Trial name
- NCT00546078
- Testing
- Cervarix™
- Where
- 17 sites in United States, Canada
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infection, HIV Infection
Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)
This is a observational study aims to assess anal and genital human papillomavirus (HPV) infection status among men who have sex with men (MSM) in China, and their knowledge and attitude about HPV vaccine.
- Conditions
- HPV Infection, HIV Infection, Syphilis
- Trial name
- NCT01300689
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
HPV, Vaccine Acceptance
Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention
This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.
- Conditions
- HPV, Vaccine Acceptance, Vaccine Decision Making, HPV Vaccination
- Trial name
- HPV-END-IT (NCT07632963)
- Testing
- HPV-Kompassen
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
HPV Infections
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
To prove that quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine is generally safe and well tolerated in the Chinese population.
- Trial name
- NCT00635830
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus
Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging
Background: Prevention of cervical cancer and genital warts could be achieved by immunization with the prophylactic human papillomavirus (HPV) vaccines commercially available. However, in the U.S.
- Trial name
- NCT03759236
- Testing
- Health Messaging via SMS, CDC Health Pamphlets
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Papillomavirus Infections
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
The purpose of this study is to evaluate the safety, tolerability, and the immunological effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in healthy adults.
- Trial name
- NCT03929172
- Testing
- AAVLP-HPV
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- 2A Pharma AB